Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation

Toripalimab

the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.

Conventional segmental radiotherapy

The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab

opreation

Wang Buhai, doctor

Buhai Wang, MD/PhD

Yusheng Shu, MD/PhD

Liqin Liu, master

Shichun Lu, master

Yichen Liang, MD

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

The Efficacy and Safety of Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIB-IIIA Non-small Cell Lung Cancer

PD-L1 expression of tissue specimens、TMB、WES and changes of ctDNA in peripheral blood

Major pathological response rates assessed by independent center pathology

The time from the beginning of enrollment to the occurrence of any events, including death, disease progression, change of chemotherapy regimen, change of chemotherapy, addition of other treatments, the occurrence of fatal or intolerant side effects and other events

Kaplan-Meier median estimates and curves will be used to describe OS survival functions

Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review.

Some time until the tumor recurs or die for various reasons

Adverse events are defined as any adverse medical events that occur in the participants taking the drugs and do not necessarily have a causal relationship with the treatment. AEs/SAEs were evaluated using NCI-CTCAE v5.0

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer	NCT06065813	Non-small Cell ... Neoadjuvant The... Radiotherapy Immunotherapy	Toripalimab Conventional se... opreation	18 Years - 70 Years	Northern Jiangsu People's Hospital
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer	NCT06065813	Non-small Cell ... Neoadjuvant The... Radiotherapy Immunotherapy	Toripalimab Conventional se... opreation	18 Years - 70 Years	Northern Jiangsu People's Hospital

Spots Global Cancer Trial Database for opreation

Every month we try and update this database with for opreation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for opreation

Every month we try and update this database with for opreation cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for opreation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.